文献速递糖尿病

人群特异性Thr44Met OCT3编码变异影响二甲双胍药代动力学并在C57Bl/6J小鼠中影响胰岛素敏感性

The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice.
PubMed 文献 · Diabetologia · 2024-10-18

在310名新西兰毛利与太平洋裔人群中,SLC22A3 rs8187715(p.Thr44Met)次要等位基因频率为15.4%,与常见代谢参数无关联。在C57BL/6J背景的同源敲入小鼠中,该变异加速二甲双胍入血和组织摄取,急性给药改善胰岛素敏感性,但长期给药后此效应消失。

要点

  • rs8187715在毛利与太平洋裔参与者中次要等位基因频率为15.4%。
  • 该变异在敲入小鼠中加速二甲双胍入血和组织摄取。
  • 急性二甲双胍给药改善变异敲入小鼠胰岛素敏感性,长期给药后效应消失。

核心结论

  • SLC22A3 rs8187715变异在体内加速二甲双胍摄取速率,急性改善胰岛素敏感性但长期给药无增强效应,该变异在毛利与太平洋裔中高 prevalence,为潜在人群特异性药物遗传标记。

研究设计与样本

  • 对310名在新西兰招募的毛利与太平洋裔个体进行rs8187715基因分型,并采用C57BL/6J背景的同源敲入小鼠模型研究该变异。

主要发现

  • 毛利与太平洋裔参与者中该变异次要等位基因频率为15.4%。
  • 该变异与糖尿病状态、BMI、血压、血脂、血糖和HbA1c等常见代谢参数无关联。
  • 在敲入小鼠模型中,二甲双胍入血和组织摄取速率增加。
  • 急性二甲双胍给药增加变异敲入小鼠胰岛素敏感性,但长期二甲双胍治疗后该效应消失。
  • 长期二甲双胍治疗下,变异敲入小鼠中二甲双胍对GDF-15水平的影响也消失。

临床怎么用

  • 作者认为该变异在毛利与太平洋裔中高 prevalence,为潜在人群特异性药物遗传标记,有潜力指导这些人群的二甲双胍治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metformin is an important first-line treatment for type 2 diabetes and acts by increasing the body's ability to dispose of glucose. Metformin's efficacy can be affected by genetic variants in the transporters that regulate its uptake into cells. The SLC22A3 gene (also known as EMT; EMTH; OCT3) codes for organic cation transporter 3 (OCT3), which is a broad-specificity cation transporter that also transports metformin. Most SLC22A3 variants reduce the rate of metformin transport but the rs8187715 variant (p.Thr44Met) is reported to increase uptake of metformin in vitro. However, the impact of this on in vivo metformin transport and efficacy is unknown. Very few carriers of this variant have been reported globally, but, notably, all were of Pacific Island descent. Therefore, this study aims to understand the prevalence of this variant in Polynesian peoples (Māori and Pacific peoples) and to understand its impact on metformin transport and efficacy in vivo. METHODS: rs8187715 was genotyped in 310 individuals with Māori and Pacific ancestry recruited in Aotearoa New Zealand. To study this variant in a physiological context, an orthologous knockin mouse model with C57BL/6J background was used. Pharmacokinetic analysis compared uptake rate of metformin into tissues. Plasma growth/differentiation factor 15 (GDF-15) was also measured as a marker of metformin efficacy. Glucose and insulin tolerance was assessed after acute or sustained metformin treatment in knockin and wild-type control mice to examine the impact of the variant on metformin's glycaemic control. RESULTS: The minor allele frequency of this variant in the Māori and Pacific participants was 15.4%. There was no association of the variant with common metabolic parameters including diabetes status, BMI, blood pressure, lipids, or blood glucose and HbA1c. However, in the orthologous knockin mouse model, the rate of metformin uptake into the blood and tissues was increased. Acute metformin dosing increased insulin sensitivity in variant knockin mice but this effect was lost after longer-term metformin treatment. Metformin's effects on GDF-15 levels were also lost in variant knockin mice with longer-term metformin treatment. CONCLUSIONS/INTERPRETATION: These data provide evidence that the SLC22A3 rs8187715 variant accelerates metformin uptake rate in vivo. While this acutely improves insulin sensitivity, there was no increased effect of metformin with longer-term dosing. Thus, our finding of a high prevalence of this variant specifically in Māori and Pacific peoples identifies it as a potential population-specific pharmacogenetic marker with potential to guide metformin therapy in these peoples.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wang Q, Leask MP, Lee K, et al. The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice. Diabetologia. 2024. PMID: 39422716. doi:10.1007/s00125-024-06287-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。